Biotricity (NASDAQ:BTCY) Receives Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Biotricity (NASDAQ:BTCY) in a report published on Monday,Benzinga reports. HC Wainwright also issued estimates for Biotricity’s Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.67) EPS.

Biotricity Stock Down 11.8 %

Shares of BTCY opened at $0.28 on Monday. Biotricity has a 12-month low of $0.19 and a 12-month high of $1.67. The business has a 50-day simple moving average of $0.34 and a two-hundred day simple moving average of $0.63. The stock has a market cap of $6.28 million, a PE ratio of -0.23 and a beta of 1.22.

Biotricity (NASDAQ:BTCY) last issued its earnings results on Monday, August 19th. The company reported ($0.49) earnings per share (EPS) for the quarter. The business had revenue of $3.20 million during the quarter. On average, equities research analysts expect that Biotricity will post -0.67 EPS for the current year.

Hedge Funds Weigh In On Biotricity

A hedge fund recently bought a new stake in Biotricity stock. AE Wealth Management LLC purchased a new stake in Biotricity, Inc. (NASDAQ:BTCY) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 97,751 shares of the company’s stock, valued at approximately $88,000. AE Wealth Management LLC owned about 0.45% of Biotricity at the end of the most recent quarter. 3.89% of the stock is owned by institutional investors and hedge funds.

About Biotricity

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.